Eurofins expands Central Laboratory Shanghai facility

by Jesse Gehris, Marketing Associate, Eurofins Central Laboratory

In 2017, China became the world’s second-largest national pharmaceutical market, due to its aging population and rising medical needs. In its ongoing commitment to adapt to emerging trends in the pharmaceutical industry, Eurofins Central Laboratory, a member of Eurofins BioPharma Services, has expanded its facility in Shanghai, China. Since 2015, the China National Drug Administration (CNDA), formerly China Food and Drug Administration (CFDA), has increased its focus on quality driven laboratory data, revising regulations, and creating new enforcement standards. In light of these events, companies have engaged international central lab providers, like Eurofins, to ensure quality data is produced to global standards. Eurofins Central Laboratory continuously monitors both data quality and laboratory operations in its Shanghai, China, facility in accordance with GCP, GLP, CAP and NGSP Level 1 accreditations. This focused effort on quality operations is reflected with the Shanghai location having successful CNDA inspections twice, with no major findings, in the last three years.

The expansion of the Shanghai facility is in response to the growth of clinical trials conducted in China, originating from both Eurofins’ International and Intra-China client base. Also, this facility supports comprehensive Central Laboratory Services (safety, efficacy and biomarkers), BioAnalytical Services (Ligand Binding Assays, neutralising anti-bodies, plate based immunogenicity capabilities), and Kit Packing capabilities. Eurofins Central Laboratory deploys Lean, globally standardised processes, enabling high quality GMP and FDA/CNDA/EMA compliant specimen and transportation kits to be distributed worldwide. Each year, Eurofins Central Laboratory produces and ships approximately 800,000 specimen collection and transportation kits to investigator sites all over the world.

With 30 years of experience serving the pharmaceutical and biotech industry, Eurofins looks forward to providing dedicated services to this critical market and region, with continuously expanded analytical capabilities and service offerings.

For more information visit: www.eurofinscentrallaboratory.com